Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Decibel Therapeutics

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

Hearing loss prevention drugs expected by 2020

Report by Action on Hearing Loss launched today

- PMLiVE

Top biotech firms saw sales jump in 2014

But rate of growth slowing from the past five years according to new analysis

Sanofi reception

Monthly dosing effective for Sanofi’s alirocumab

New data puts pressure on Amgen's evolocumab

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

- PMLiVE

Regeneron top science employer, says survey

Ranked highest for third year in a row

- PMLiVE

Amgen files lawsuit to block PCSK9 rivals

Firm suing Sanofi and Regeneron for patent infringement

Sanofi reception

Trial suggests Sanofi’s asthma drug works in sinusitis

Dupilumab able to reduce polyp size in sinusitis patients

- PMLiVE

Sanofi/Regeneron’s alirocumab ‘cuts cardiovascular events’

Data presented at ESC Congress demonstrates lower rates of cardiac death, stroke and more

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

Bayer symbol

Bayer and Regeneron to develop second wet AMD therapy

Will collaborate on drug to be used in combination with Eylea

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links